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Abstract
Disease progression models are instrumental in predicting individual-level health trajectories and un-
derstanding disease dynamics. Existing models are capable of providing either accurate predictions
of patients’ prognoses or clinically interpretable representations of disease pathophysiology, but not
both. In this paper, we develop the phased attentive state space (PASS) model of disease progression,
a deep probabilistic model that captures complex representations for disease progression while main-
taining clinical interpretability. Unlike Markovian state space models which assume memoryless
dynamics, PASS uses an attention mechanism to induce "memoryful" state transitions, whereby
repeatedly updated attention weights are used to focus on past state realizations that best predict
future states. This gives rise to complex, non-stationary state dynamics that remain interpretable
through the generated attention weights, which designate the relationships between the realized
state variables for individual patients. PASS uses phased LSTM units (with time gates controlled
by parametrized oscillations) to generate the attention weights in continuous time, which enables
handling irregularly-sampled and potentially missing medical observations. Experiments on data
from a real-world cohort of patients show that PASS successfully balances the tradeoff between
accuracy and interpretability: it demonstrates superior predictive accuracy and learns insightful
individual-level representations of disease progression.
Keywords: Disease progression modeling, recurrent neural networks, state-space models
1. Introduction
Chronic diseases – such as cardiovascular disease, cancer and diabetes – progress slowly throughout
a patient’s lifetime, causing increasing burden to the patients, their carers, and the healthcare delivery
system Sevick et al. (2007). Modern electronic health records (EHR) keep track of individual patients’
disease progression trajectories through follow-up data sequences of the form (X1, ...,Xt), where Xt
is a set of clinical observations collected for the patient at time t. The advent of EHRs1 provides an
opportunity for building models of disease progression that can fulfill two central goals of healthcare
delivery systems:
1. https://www.healthit.gov/sites/default/files/briefs/
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(d) Unrolled graphical depiction for an attentive state space
Figure 1: Depictions for different models of sequential data: (a) Graphical model for an RNN. ♦ denotes a deterministic
intermediate representation, (b) Graphical model for an HMM.© denotes probabilistic states, (c) Graphical model for the
proposed attentive state space model. (c) Unrolled graphical depiction for an attentive state space. Thickness of the arrows
reflect the attention weights.
 Goal A: Predicting individual-level disease trajectories.
 Goal B: Understanding disease progression mechanisms.
Goal A entails the supervised problem of predicting future clinical observations (Xt+1,Xt+2, . . .) on
the basis of past observations (X1, . . .,Xt). Goal B entails the unsupervised problem of discovering
clinically-interpretable latent structures that explain the mechanisms underlying disease progression.
Both goals A and B are entangled. This is because accurate predictions need to be transparent and
interpretable in order to ensure their actionability, whereas interpretable representations explaining
disease progression can only be trustworthy if they possess high predictive power.
Unfortunately, as a consequence of the inherent tension between model accuracy and inter-
pretability Lipton (2016), most existing models of disease progression fulfill either Goal A or Goal
b, but not both. State-of-the-art prediction performance is achieved by models based on recurrent
neural networks (RNN) Lim and van der Schaar (2018); Lipton et al. (2016); Choi et al. (2016a).
RNN-based models are often used for sequence prediction (or sequence labeling), where they are
trained to estimate the predictive distribution P (Xt |Xt−1, ...,X1) by propagating a sequence of
hidden states (Z1, ...,Zt) through intermediate deterministic mappings (Figure 1a). Unfortunately, an
RNN is of a "black-box" nature since its hidden states (Z1, ...,Zt) do not explicitly map to clinically
meaningful states of disease progression. On the contrary, state space approaches based on Hidden
Markov Models (HMM) provide a natural interpretation of a disease trajectory as a sequence of
transitions between latent "progression stages" (Z1, ...,Zt) (Figure 1b), each of which corresponds to
a clinically distinguishable disease state Alaa and van der Schaar (2018); Liu et al. (2015); Wang
et al. (2014). However, the interpretability of HMMs comes at a price. That is, while RNNs can in
principle approximate any dynamical system, an HMM is limited to memoryless Markovian state
dynamics, which greatly undermine its predictive performance.
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Our Contribution In this paper, we develop a deep probabilistic model of disease progression
that capitalizes on both the predictive power of RNNs and the interpretable nature of state space
models to fulfill Goals A and B. Our model maintains the probabilistic structure of a state space
representation, which decouples emission and transition distributions, but uses an RNN to model
a flexible non-Markovian state transition dynamic P (Zt |Zt−1, ...,Z1) that allows future states to
depend on all past states. To model state transitions, we use an attention mechanism whereby the
RNN generates a (repeatedly updated) set of attention weights (α1, ...,αt) that designate the (relative)
influence that past state realizations (Z1, ...,Zt) have on the transition probabilities to the future state
Zt+1. Our model for state transitions can be summarized as follows:
(αt1, ...,α
t
t) = RNN(X1, ...,Xt),
P (Zt+1 = z) =
∑
i≤t
αti × P (Zt = z |Zi = z′).
The model described above, which we call an attentive state space model, uses a set of RNN-
generated attention weights to induce a time-varying Markov blanket for the state variable Zt. This
Markov blanket changes for every new state transition, putting more or less attention on previous
state realizations depending on the patient’s clinical history. If we restrict the attention weights to
be binary (αti ∈ {0, 1},∀i ≤ t), the attentive state space becomes a variable-order Markov model
that decides the extent of memory involved in state transitions in every time step depending on the
patient’s current context. This allows for realistic non-stationary and time-inhomogeneous dynamics
that are implicitly captured by an RNN but could not be possibly modeled with an HMM. The
attentive state representation is clinically interpretable because the complex state dynamics that it
captures are fully explicable through the attention weights, which indicates the extent to which past
clinical events contribute to future state realizations. Figure 1c provides a formal graphical model for
our attentive state space representation. Figure 1d shows an unrolled graphical depiction of the model
for a particular exemplary patient, highlighting the time-varying nature of the attention weights and
their straightforward interpretational benefit.
Because EHR data comprises irregularly-sampled and asynchronous observations gathered only
at the times when the patient visits a hospital, we use the phased LSTM units introduced in Neil et al.
(2016), with time gates controlled by parametrized oscillations, in order to generate the attention
weights at arbitrary time instances. Thus, we call our model a phased attentive state space (PASS)
model. A detailed description of the construction of the PASS model is provided in Section 2. A
detailed comparison between PASS and related models can be found in Section 4.
Indeed, state inference and parameter estimation of PASS is nontrivial since non-Markovianity
hinders the application of conventional backward message passing algorithms Alaa and van der
Schaar (2018); Dai et al. (2016). In Section 3, we show that PASS can be re-parameterized as a non-
stationary dynamic Bayesian network, for which conventional forward message passing algorithms
can be implemented with a complexity resembling that of the forward filtering algorithm used for
HMMs. We conduct parameter estimation via a variant of the Expectation-Maximization algorithm.
In Section 5, we conduct experiments on data from a real-world longitudinal cohort of more than
10,000 Cystic Fibrosis (CF) patients. Our experiments show that PASS successfully balances the
tradeoff between accuracy and interpretability: it demonstrates superior predictive accuracy and
learns insightful individual-level representations of disease progression. In particular, we show that
PASS learns meaningful population-level CF progression stage, and that the attention weights can
inform treatment decisions on the level of individual patients.
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2. A Phased Attentive State-space Model of Disease Progression
We model the progression of a target chronic disease using longitudinal EHR data for patients who
have developed, or are at risk of developing such disease. We start by describing the model variables
in Section 2.1, and then we develop the attentive state dynamics in Sections 2.2 and 2.3.
2.1 Model Variables and Notation
Structure of the EHR data A patient’s EHR record, denoted as D, is a collection of timestamped
follow-up data gathered during repeated, irregularly-spaced hospital visits, in addition to static
features (e.g., genetic variables). We represent a given patient’s EHR record as follows:
D = {Y }
Static features
∪ {(Xm, tm
Visit times
)}Mm=1, (1)
where Y is the static features’ vector, Xm is the follow-up data collected in the mth hospital visit, tm
is the time of the mth visit, and M is the total number of hospital visits. (The time-horizon t is taken
to be the patient’s chronological age.) The follow-up data Xm comprises information on biomarkers
and clinical events, such as treatments and diagnoses of comorbidities. (Refer to the Appendix for
a more elaborate discussion on the type of follow-up data collected in EHRs.) An EHR dataset
{D(i)}Ni=1 is an assembly of records for N independent patients.
Disease progression stages We assume that the target disease evolves through D different
progression stages. Each stage corresponds to a distinct level of disease severity that manifests
through the follow-up data. We model the evolution of progression stages via a (continuous-time)
stochastic process Z(t) of the following form:
Z(t) =
∑
n∈N+
Z˜n · 1{Tn<t≤Tn+1}, Z˜n ∈ {1, . . ., D},
where {Tn}n is the sequence of onsets for the realized progression stages, and Z˜n is the progression
stage occupying the interval (Tn, Tn+1]. We assume that Z(0) = 1 (i.e., Z˜1 = 1) almost surely, with
stage 1 being the asymptomatic stage designating "healthy" patients. The sequence {Zm}m is the
embedded discrete-time process induced by Z(t) at the hospital visit times {tm}m, i.e. Zm = Z(tm).
2.2 Attentive State Space Representation
We adopt a state space representation for the disease progression process, with the state space being
the set of all stages of progression {1, . . . , D}. The states’ sequence {Zm}m is hidden whereas the
EHR data D is observed. We consider a graphical model that defines probabilistic dependencies
between {Zm}m and D through the following factorization of emission and transition distributions:
P ({Zm}m, {Xm}m |Y , {tm}m) =
m∏
m′=1
P (Xm′ |Zm′)︸ ︷︷ ︸
Emission
· P (Zm′ | Ftm′−1)︸ ︷︷ ︸
Transition
, (2)
where Ftm′ = {Y , (Z1,X1, t1), . . . , (Zm′ ,Xm′ , tm′)} conveys all the information available in the model
up to time tm′ . We model the emission distribution in (2) as a Gaussian distribution with state-specific
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parameters as follows:
P (Xm |Zm = z) = N (µz,Σz), z ∈ {1, . . . , D}. (3)
Binary variables are modeled with a Bernoulli state-specific distributions. The transition probability
factor in (2) assumes that the realized state at time tm depends on the entire process history Ftm−1 .
To model P (Zm′ | Ftm′−1), we first define a D ×D baseline Markov generator matrix Λ as follows:
Λ =

−λ12 λ12 0 . . . 0
0 −λ23 λ23 . . . 0
...
...
. . .
...
...
0 . . . 0 −λD−1,D λD−1,D
0 . . . 0 0 0
 , (4)
λij ≥ 0, ∀i, j ∈ {1, . . . , D}, where λij is a Markovian transition rate from state i to state j. Λ is the transi-
tion rate matrix of a continuous-time Markov chain model on the state space {1, . . . , D}; its bidiagonal
structure forces transitions to be permissible only between adjacent states (in an ascending order),
with the last state (state D) being an absorbing state. This enforces the states in the set {1, . . . , D} to
map properly to the disease progression stages (state 1 is the least severe stage and state D is the
terminal stage of illness). We model the state transition probability P (Zm = z | Ftm−1) by creating a
"memoryful" version of the Markov chain model in (4) through the following parametrization:
P (Zm = z | {(Zk = zk,αmk ,∆k)}m−1k=1
Sufficient statistics
) =
m−1∑
k=1
αmk
Attention weights
(e∆k Λ)z,zk , (5)
where ∆k = tm − tk is the time interval between the kth and the mth hospital visits, αmk ∈ [0, 1] is an
attention weight assigned to the kth visit, with
∑m−1
k=1 α
m
k = 1, and (e∆k Λ)z,zk is entry (z, zk) of the
exponentiation of matrix Λ. The attention weights in (5) are generated via an attention function ϕ
with parameter Θ as follows:
(αm1 , . . . ,α
m
m−1) = ϕ(Y , tm, {(X1, t1)}m−1j=1 ; Θ). (6)
We call the representation in (5) an attentive state space representation. As shown in (5), the
attentive representation starts with a baseline Markov chain, and creates memory in state transitions
by weighting the baseline Markovian transition probabilities from all previous states, i.e. {e∆kQ}m−1k=1 ,
using a set of attention weights {αmk }m−1k=1 . (The attention weights are generated on the basis of a
patient’s static features and follow-up data.) That is, instead of the memoryless Markovian dynamics
in which a new state realization Zm+1 is fully determined by the current realization Zm, the attentive
state dynamics pay attention to all previous realizations in proportion to their attention weights. This
gives rise to "memoryful", non-stationary, and time-inhomogeneous state transitions, whereby the
time-varying Markov blanket (sufficient statistic) {(Zk,αmk ,∆k)}m−1k=1 of every new state realization
Zm determines which state realizations in the past matter most for the future.
5
ALAA AND VAN DER SCHAAR
Similar to an HMM model, the factorization in (2) decouples the transition and emission distribu-
tions by assuming that Zm d-separates Xm from all other variables. This decoupling ensures that the
clinical interpretability of the hidden states is maintained since each state is associated with a distinct
emission distribution for the observed follow-up data. Moreover, regardless of the choice of the
attention function ϕ, the attentive state transition matrix
∑m−1
k=1 α
m
k e
∆k Λ will always be interpretable
because the influence that a previous progression stage has on the future progression trajectory is
encoded in its corresponding attention weight.
2.3 The Phased Attention Mechanism
To implement the attentive state dynamics, the attention weights in (6) must be repeatedly updated
(after each hospital visit) using variable-length sequences of data. Hence, we model the attention
function ϕ as an RNN that maps a patient’s history to attention weights as follows:
hm−1, . . . ,h1 = pLSTM ({(X˜m−j ,∆j,m)}m−1j=1 ); Θ),
ej = w
Thj + b, ∀j ∈ {1, . . . ,m− 1},
(αm1 , . . . ,α
m
m−1) = Softmax(e1, . . . , em−1), (7)
where ∆j,m = tm−j+1 − tm−j , pLSTM is a phased LSTM network Neil et al. (2016), w and b are the
output layer parameters, hj is the hidden layer, and X˜j = [Y ,Xj , tj ] is the input at time step j. Unlike
traditional RNNs, a phased LSTM takes a timestamped sequence as an input, and performs updates at
arbitrary points of time. Phased LSTMs can also handle asynchronously-sampled sequences, which
is particularly important for EHR data as not all of the components of Xm are necessarily measured
in each hospital visits. Through phased LSTMs, we can update the attention weights with whatever
follow-up data available at arbitrary time instances without the need for explicitly imputing missing
observations. We call the attention mechanism in (7) the phased attention mechanism. The PASS
model is an attentive state space model that uses the phased attention mechanism.
In the mth time step, phased attention operates by feeding the phased LSTM with the sequence
{X˜j}m−1j=1 in reversed order, with timestamps reversed and shifted by tm as shown in Figure 2 (left).
This allows all attention weights allocated to all previous state realizations (or equivalently, hospital
visits) to be dynamically updated at every time step while preserving the relative time spacing
between hospital visits. The phased attention mechanism in (7) can be thought of as a continuous-
time analogue of the reverse-time attention mechanism in Choi et al. (2016b).
The main difference between the phased LSTM model and the conventional LSTM model is the
addition of a time gate, gt, which controls the updates to the LSTM cell state ct (and consequently the
hidden layer ht). The opening and closing of the time gate gt for every neuron is controlled through
an independent (continuous-time) rhythmic oscillation specified by 3 parameters (an oscillation
period, a phase shift, and the ratio of the duration of the "open" phase to the full period) that can be
learned from the data Neil et al. (2016). With every neuron having its own oscillatory parameters,
the phased LSTM generates a continuum of possible updates that can be probed at arbitrary time
instances as illustrated in Figure 3 (right). The updated equations of the phased LSTM can be found
in Neil et al. (2016).
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Figure 2: Illustration of phased attention mechanism. Left: Architecture of the phased attention network. The follow-up
data (augmented with the static features) are fed in a reversed order into the phased LSTM, with reversed and shifted
timestamps for the hospital visits. Right: Illustration for the operation of the phased LSTM. The time gate gt of 4 neurons
are depicted; each has different oscillatory parameters. The contents of the cell state ct decay as we go backwards in time,
implying lesser attention for older hospital visits.
3. Learning and Inference
In this Section, we present the parameter learning and state inference algorithms for the PASS model.
Throughout this Section, we continue with a single patient EHR record for the ease of notation.
Parameter learning Let Γ be the set of all PASS model parameters, i.e. Γ = {Λ, (µ,Σ),Θ},
where µ = {µz}Dz=1 and Σ = {Σz}Dz=1 are the emission parameters. The complete data log-likelihood
of an EHR record D and a state sequence realization {Zm = zm}m is given by:
log(P (D, {zm}Mm=1 |Γ)) =
M∑
m=1
log
(
m−1∑
k=1
αmk · exp(Λ (tm − tk))zk,zm
)
. (8)
Because the state sequence {Zm}m is hidden, the complete data likelihood in (8) is inaccessible,
and hence we resort to the Expectation-Maximization (EM) algorithm. The EM algorithm operates
iteratively to update its guess of Γ, where the ith iteration implements 2 steps:
E-step: Q(Γ | Γˆ(i)) = E [ log (P (D, {Zm}m)) ] ,
M-step: Γˆ(i+1) = argmaxΓQ(Γ | Γˆ
(i)
). (9)
Algorithm 1 lists the steps involved in implementing the EM algorithm in (9). In Step 1, we first
infer the hidden states via a message passing algorithm (described later) using the current guess of
Γ. Next, in Steps 2 and 3, we compute the attention weights associated with all hospital visit times,
and then compute the transition probabilities using the formula in (5). In Step 4, the phased LSTM
parameters are updated by optimizing the cross-entropy loss of the estimated transition probabilities
and the inferred states. Maximum-likelihood is used to update the emission and transition parameters
using the complete data likelihood obtained by plugging the inferred states into the expression in (8).
To updated the Markov generator matrix Λ, we use the Expm method in Liu et al. (2015).
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Algorithm 1 EM algorithm for learning the PASS model parameters
Input: EHR dataD, initial guess Γˆ(0), state space {1, . . ., D} and number of iterations R.
Output: Parameter estimate Γˆ = {Λˆ, (µˆ, Σˆ), Θˆ}
while i ≤ R do
1 • {zˆm}m ← Forward-Backward(D | Γˆ(i))
2 • (αˆm1 , . . . , αˆmm−1)← ϕ((X˜m−1, tm− tm−1), . . . , (X˜1, tm− t1); Θˆ
(i)
), m ∈ {1, . . .,M}
3 • pˆm ←
∑m−1
k=1 αˆ
m
k (e
∆k Λˆ
(i)
)zˆ,zˆk m ∈ {1, . . .,M}
4 • Θˆ(i+1) ← argmin (−∑m zˆm · log(pˆm))
5 • Λˆ(i+1) ← argmax log(P (D | {zˆm}Mm=1,Λ)
6 • (µˆ(i+1), Σˆ(i+1))← argmax log(P ({Xm}m | {zˆm}Mm=1)
7 • i← i+ 1
end while
Figure 3: Rearranged super states for the attentive model in Figure 1c with truncated attention and Q = 1. The resulting
graphical model (right) corresponds to a standard Hidden Markov model.
State inference One key advantage of the attentive state construction in (8) is that the attention
weights explicitly quantify the importance of each past state to any given future state. Thus, efficient
inference can be conducted by limiting the Markov blanket for every state variable to "important"
past states with attention weights exceeding a certain threshold. Since attention weights already
decline as we go back in time, we approximate the Markov blanket for every state Zm by only
considering the Q most recent states (Zm−1, . . .,Zm−Q). The resulting graphical model can be
rearrange by lumping together every Q consecutive states into one "super state" (as shown in Figure
3), we retrieve a first-order Markovian dynamic Bayesian network (or equivalently, a higher-order
Markov model Murphy and Russell (2002)), for which standard forward and backward message
passing apply.
4. Related Works
Previous works related to PASS fall into three areas: state space models of disease progression,
RNN-based predictive models for healthcare applications, and (general-purpose) deep probabilistic
models. In what follows, we discuss previous works in these three areas, and then conclude the
Section by demonstrating the generality of the PASS model.
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State space models of disease progression Almost all existing models of disease progression
are based on variants of the HMM model Wang et al. (2014); Liu et al. (2015); Alaa et al. (2017).
Disease dynamics in such models are very easily interpretable as they can be perfectly summarized
through a single matrix of probabilities that describes the transition rates among the different disease
states. Markovian dynamics also greatly simplify inference because the model likelihood factorizes
in a way that makes efficient forward and backward message passing possible Murphy and Russell
(2002). However, memoryless Markov models assume that a patient’s current state d-separates her
future trajectory from her clinical history. This renders HMM-based models incapable of properly
explaining the heterogeneity in the patients’ progression trajectories, which often results from
their varying clinical histories or the chronologies (timing and order) of their experienced clinical
events Valderas et al. (2009). This limitation is particularly crucial in complex chronic diseases that
are accompanied with multiple morbidities. As discussed earlier, PASS addresses this limitation
by creating memoryful state transitions that depend on the patient’s entire clinical history. (In
the Appendix material, we provide a detailed discussion on how PASS can better explain patient
heterogeneity compared to Markov models.)
RNN-based predictive modeling for healthcare Various RNN-based predictive models have
been recently developed for healthcare settings; examples of such models include Doctor AI Choi
et al. (2016a), L2D Lipton et al. (2016), and Disease-Atlas Lim and van der Schaar (2018). All
those methods do not attempt to model a disease progression trajectory, but rather predict target
clinical events on the basis of (discrete) sequential observations. Because of their black-box nature,
none of these models can help understand the mechanisms underlying disease progression.
There have been various attempts to create interpretable RNN-based predictive models using
attention. The models in Choi et al. (2016b) and Ma et al. (2017) use the reverse-time attention
mechanism to learn visit-level and variable-level attention weights that explain the prediction of a
target label through measures of variable importance. The phased attention mechanism proposed in
Section 2.3 is a generalization of the reverse-time attention mechanism in Choi et al. (2016b) that
can operate in continuous-time, and update the attention weights at irregularly-spaced and potentially
incomplete observations. The main difference between the way attention is used in PASS and the
way it is used in models like RETAIN Choi et al. (2016b) can be summarized as follows. PASS
applies attention to the latent state space, whereas RETAIN applies attention to the observable sample
space. Hence, the attention mechanism gives different types of explanations in the two models. In
PASS, the phased attention mechanism interprets the hidden disease dynamics, and hence it provides
an explanation for the mechanisms underlying disease progression. On the contrary, RETAIN uses
attention to measure feature importance, and hence it only explains predictions, but does not explain
the disease progression mechanisms.
Deep probabilistic models Most existing works on deep probabilistic models have focused
on developed structured inference algorithms for deep Markov models and their variants Krishnan
et al. (2017); Dai et al. (2016); Karl et al. (2016); Johnson et al. (2016). All such models use
neural networks to model the transition and emission distributions, but are limited to Markovian
dynamics. Other works develop stochastic versions of RNNs for the sake of generative modeling;
examples include variational RNNs Chung et al. (2015), SRNN Fraccaro et al. (2016), and STORN
Bayer and Osendorfer (2014). All such models augment stochastic layers to an RNN in order
to enrich its output distribution. However, the transition and emission distributions in all these
models cannot be decoupled, and hence their latent state representations would not lead to clinically
meaningful identification of disease states. To the best of our knowledge, PASS is the first deep
9
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probabilistic model that provides both a clinically interpretable latent representation, and interpretable
non-Markovian state dynamics.
Generality of the attentive state space representation For particular choices of the attention
function in (6), the attentive state space representation in (5) reduces to various classical models of
sequential data. For instance, if ϕ always sets αmm−1 to 1 and all other weights to 0, then we retrieve
an HMM. If the attention weights are binarized, then we retrieve a variable-order HMM Willems
et al. (1995); Begleiter et al. (2004). Furthermore, if the attention weights are fixed, then we recover
an auto-regressive model. This is a powerful feature of our model as it implies that by learning
the attention function ϕ, we are effectively testing the assumptions of various commonly-used time
series models in a data-driven fashion.
5. Experiments
To validate the PASS model, we conducted a set of experiments using retrospective data for a
longitudinal cohort of cystic fibrosis (CF) patients. CF is a life-shortening chronic condition that
causes severe lung dysfunction, and is the most common genetic disease in Caucasian populations
Szczesniak et al. (2017). All experimental details are listed hereunder.
Recall that, as stated in Section 1, the main purpose of the PASS model is to simultaneously
fulfill Goal A (predicting individualized disease trajectories) and Goal B (understanding disease
progression mechanisms). Thus, in Sections 5.1 and 5.2, we evaluate our model with respect to both
goals.
Data description. The dataset involved in the experiments was extracted from the UK CF
registry, a database maintained by the UK CF trust2. Data was gathered from hospitals all over
the UK, with 99% of patients consenting to their data being submitted, and hence the cohort is
representative of the UK CF population. The dataset comprises longitudinal follow-ups for 10,263
patients over the period spanning between 2008 and 2015, with a total of 60,218 hospital visits. Each
patient is associated with 90 variables, including the intake of 36 possible treatments, diagnoses for
31 possible comorbidities and 16 possible infections, FEV1 biomarkers, gender, and CF genetic
mutations.
5.1 Goal A: Predicting individual-level CF progression trajectories
Baselines. We compared the predictive accuracy of PASS to the following models:
 MLP: A multi-layer perceptron (MLP) classifier that is trained to sequentially predict the
clinical events in 1 hospital visit given the observations in the prior visits. The MLP is trained
on a static dataset that is created by unrolling the longitudinal follow-up data for all patients
and treating every hospital visit as a separate data point.
 HMM: A standard continuous-time HMM model Wang et al. (2014); Liu et al. (2015) trained
with the Baum-Welch EM algorithm. The number of HMM states was set via the Akaike
information criterion (AIC). Similar to the PASS model, the observations (X1, . . .,Xt) are
modeled as Gaussian emission variables with state-specific mean and variance parameters.
 RNN: A standard LSTM network with 2 hidden layers of size 200. The follow-up data
(X1, . . .,Xt) was used as an input, and the output was defined as a set of (binary) labels
2. https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/
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ABPA Diabetes I. Obstruction K. Pneumoniae E. Coli Aspergillus
Model AUC-ROC AUC-ROC AUC-ROC AUC-ROC AUC-ROC AUC-ROC
PASS 0.687± 0.022 0.771± 0.012 0.577± 0.018 0.718± 0.026 0.701± 0.019 0.640± 0.011
RETAIN 0.685± 0.026 0.764± 0.014 0.578± 0.014 0.715± 0.031 0.697± 0.015 0.641± 0.010
RNN 0.681± 0.016 0.762± 0.021 0.577± 0.010 0.719± 0.036 0.696± 0.014 0.641± 0.012
HMM 0.666± 0.021 0.755± 0.031 0.551± 0.014 0.689± 0.021 0.665± 0.013 0.620± 0.009
MLP 0.657± 0.036 0.751± 0.056 0.553± 0.024 0.685± 0.052 0.656± 0.018 0.601± 0.012
Table 1: Performance of the different competing models for the 6 prognostic tasks under consideration.
designating the prediction targets at every hospital visit. A sigmoid transformation was applied
to the top hidden layer.
 RETAIN: An RNN-based reverse-time attention model proposed in Choi et al. (2016b). To
ensure a fair comparison with PASS and the standard RNN benchmark, we implemented
the attention layer of RETAIN via an LSTM with 2 hidden layers of size 200, and restricted
its architecture to generate only visit-level attention. (This is equivalent to the RNN-αM
benchmark in Choi et al. (2016b).)
The baseline algorithms above are selected so as to highlight the added value of every modeling
component in PASS. That is, an MLP only uses current information to predict the future clinical
outcomes, whereas an HMM only looks 1 step back but provides a fully-fledged probabilistic model
for disease progression. On the other hand an RNN capture more flexible dynamics (and is more
memoryful) than an HMM but lacks interpretability, whereas RETAIN can provide explanations for
its predictions, but does not explain the actual mechanisms of disease progression.
Implementation of PASS. We implemented the phased LSTM in Section 3 with 2 hidden layers
of size 200 in order to match the model complexity of RETAIN and the standard RNN baseline.
Hospital visits after which a death event happens within 3 years were explicitly labeled as the
absorbing state D in our model. The number of states D was tuned via cross-validation to optimize
the accuracy of predicting mortality events. PASS was implemented in Tensorflow Abadi et al.
(2016), and the phased attention layer was implemented via tf.contrib.rnn.PhasedLSTMCell.
Prediction tasks and evaluation metric. All models were used to sequentially predict the
1-year risk for 6 prognostic tasks of predicting 3 comorbidities and 3 lung infections that are common
in the CF population. The comorbidities are Allergic bronchopulmonary aspergillosis (ABPA),
diabetes and intestinal obstruction. The lung infections are Klebsiella Pneumoniae, E. coli and
Aspergillus. We used the area under the ROC curve (AUC-ROC) with 5-fold cross-validation for
performance evaluation, where error counts are taken over all patients and all hospital visits.
Results. The AUC-ROC performance of all models on the 6 prognostic tasks under consideration
is provided in Table 1. We note that CF is a very complex disease, for which patients encounter
various possible comorbidities and are prescribed a wide variety of possible treatments. This leads
to each patient having a very rich clinical history that influence their outcomes. Because HMMs
fail to properly integrate the patients’ rich clinical histories into the state dynamics, they displayed
modest predictive performance on the 6 prognostic tasks. As we can see in Table 1, the HMM model
did not provide any significant improvement over the static MLP model in any of the prognostic
tasks. On the contrary, RNN-based model provided significant improvements over the static MLP
model on all of the 6 tasks. The results in Table 1 show that the predictive accuracy of PASS is
11
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Figure 4: Depiction for the distributions of clinical observations and generated attention in the 3 learned progression
stages.
comparable to that of the RNN-based models. Note that the standard RNN model issue predictions
without modeling disease progression, and hence it does not offer any interpretation benefit, whereas
RETAIN provides explanations only in the form of measures of variable importance. PASS, however,
explicitly models the CF physiology (in terms of its latent progression stages), and hence it ensures
the interpretational and modeling benefits of an HMM while maintaining the predictive accuracy of
an RNN-based predictive model.
5.2 Goal B: Understanding disease progression mechanisms
In this Section, we show that the PASS model successfully extracts meaningful clinical knowledge
about the CF progression mechanisms. We also show how the PASS model parameters can inform
clinical practitioners about the progression mechanisms for individual patients.
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CF progression stages. Unlike many other chronic diseases, current clinical guidelines do not
provide classifications for the progression stages of CF Szczesniak et al. (2017). In a completely
unsupervised fashion, the PASS model successfully learned D = 3 progression stages (Stages I, II
and III) that corresponded to clinically distinguishable levels of CF severity. The learned baseline
Markov generator matrix for the transition rates among the 3 stages is given by:
Λˆ =
−0.0578 0.0578 00 −0.0691 0.0691
0 0 0
 . (10)
From the baseline transition rates in (10), it follows that the average occupancy of a patient in Stage
I is 10.0578 = 17.30 years, and the occupancy in Stage II is around
1
0.0691 = 14.47 years. That is, a
typical patient who is born with CF progresses to Stage II by adulthood, before reaching the terminal
stage by the age of 31. These figures match the survival rates in CF populations, where the median
lifetime is known to be as low as 40 years of age McCarthy et al. (2013). Note that the baseline
generator matrix in (10) only describes population-level rates of progression: individual variability
among patients are captured via the patient-specific attention weights.
The FEV1 % biomarker is the main spirometric measure of lung function that is currently used
to guide clinical and therapeutic decisions. In order to check that the learned progression stages
correspond to different levels of disease severity, we plot the estimated emission distribution for the
FEV1 % biomarker in Stages I, II and III in Figure 4. As we can see from the emission distributions
in Figure 4, the mean values of the FEV1 biomarker in each stage were 87%, 65% and 36%,
respectively. This coincided with the current practice guidelines for referring critically-ill patients to
a lung transplant, which recommends a transplant for patients with FEV1 < 30%, monitoring for
a transplant for patients with FEV1 ranging from 30% to 80%, and no transplant for patients with
FEV1 above 80% Braun and Merlo (2011). Thus, the learned progression stages can be translated
into actionable information for clinical decision-making. We also plot the emission probabilities
(parameter of the Bernoulli distribution) for the 3 comorbidities in Table 1 at every stage. We can
also see that the incidences of comorbidities increase significantly in the more severe Stages II and
III as compared to Stage I.
In Figure 4, we also obtain the maximum a posterior inferences for the progression stages of
every individual patient as described in Section 3, and plot the average attention weights assigned to
the patients’ last 6 hospital visits in every progression stage. We found that the attentive dynamics
tend to be less relevant for patients in Stage I, where most of the attention is allocated to the most
recent visit. Memory starts getting more important in Stages II and III, where the attention weights
allocated to older hospital visits gets higher. This can be explained by the fact that patients in Stages
II and III are more likely to have been diagnosed with more comorbidities in the past, and hence
more segments of their clinical history matters for predicting their outcomes.
Significance of attention weights for individual patients. How can clinicians interpret and
make use of the generated attention weights for the patient at hand? One important way to utilize
the attention weights is to reason about the effect of different treatment decisions and how their
outcomes are impacted by the patient’s history. For the sake of illustrating this point, in Figure 5
we pick an out-of-sample patient who has repeatedly visited the hospital over the years 2012, 2013
and 2014. We see the attention weights generated by the PASS model can inform the clinician about
the potential efficacy of the Ivacaftor treatment (a gene targeted therapy Wainwright et al. (2015))
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prescribed for this particular patient in the year 2014 by predicting the risk of progression to Stage
III of lung function severity by the year 2015.
The inferred progression stage for the pa-
tient was Stage II for all of the 3 hospital
visits. We toggle the patient’s follow-up
data vector X3 (in year 2014) to let the
variable indicating the prescription of the
Ivacaftor drug be once set to 0 and once
set to 1, and compute the probability of
progressing to Stage III by the year 2015
in each case. We found that assigning Iva-
caftor treatment to this patients is actually
associated with an elevated risk of progress-
ing to the severe Stage III within 1 year.
By inspecting at the attention weights, we
found that most attention is assigned to the
most recent visit when Ivacaftor treatment
is not prescribed, but the highest attention
is paid to the follow-up data in 2012 when
Ivacaftor is prescribed.
Time 
2012 2013 2014 
Liver disease 
(ICD: K76.9) 
St
ag
e
 II
 
St
ag
e
 I 
St
ag
e
 II
I 
Ivacaftor 
No Ivacaftor 
Risk = 12.37% 
Risk = 5.15% 
Attention weights =  
[2012: 0.12, 2013: 0.25, 2014: 0.63] 
Attention weights =  
[2012: 0.42, 2013: 0.21, 2014: 0.37] 
Figure 5: Usage of the PASS attention weights to reason about
treatment decisions.
The patient’s follow-up data in year 2012 included a diagnosis with Liver disease. Hence, the
elevated risk of progression upon taking the Ivacaftor treatment may be linked to its side effects
concerning liver function complication, which may exacerbate the patient’s liver disease. The PASS
model altered the state dynamics to take into account the 2-year old follow-up data that is only
important in determining the state dynamics conditional on prescription of an Ivacaftor treatment.
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Appendix
Detailed structure of the EHR data
A patient’s EHR record, denoted as E, is a collection of timestamped follow-up data gathered during
repeated, irregularly-spaced hospital visits, in addition to static features of the patient (e.g., genetic
variables). We represent a given patient’s EHR record as follows:
E = {Y }
Static features
∪ {(Xm, tm
Visit times
)}Mm=1, Follow-up data =⇒Xm =
[
um
Treatments
, Cm
Anchors
, Om
Observations
]
,
where Y is the static features’ vector, Xm is the follow-up data collected in the mth hospital visit, tm
is the time of the mth visit, and M is the total number of hospital visits. (The time-horizon t is taken
to be the patient’s chronological age.) The follow-up data vector Xm comprises three components:
 Treatments indicator (um ∈ {0, 1}U ): A binary vector indicating the prescription of (a subset
of) U possible treatments to the patient during the mth hospital visit.
 Anchor findings (Cm ∈ {0, 1}K): A binary vector indicating the presence of concrete diag-
noses (i.e., ICD or HCPCS codes Blumenthal and Tavenner (2010)) for K distinct comorbidities
that may co-occur with the target disease.
 Clinical observations (Om ∈ RO): A set of laboratory-measured biomarkers that reflect the
severity of the target disease.
An EHR dataset D is an assembly of records for N patients, i.e., D = {E(i)}Ni=1. Figure 6 provides an
illustration for the structure of the EHR data.
Patient visit time 
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llo
w
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at
a 
B
io
m
ar
ke
rs
 
IC
D
 C
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d
es
 
21 - MAR - 2012 12 - JAN - 2014 25 - FEB - 2015 3 - DEC - 2016 15 - FEB - 2011 
K74.60 
FEV1 = 86% FEV1 = 79% FEV1 = 64% FEV1 = 52% FEV1 = 54% 
E08.9 N18.9 Z94.2 
Stage I Stage II 
Figure 6: Illustration for the structure of the EHR data.
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Comparison between Markovian and attentive state dynamics
Because Markovianity simplifies inference, most existing models of disease progression are based
on HMMs (e.g., Alaa et al. (2017), Liu et al. (2015), and Wang et al. (2014)). However, memory-
less Markovian dynamics hinder a model’s capacity for "explaining" individual-level progression
trajectories. This is because under a Markov model, all patients at the same stage of progression
would have the same expected future trajectory, irrespective of their potentially different individual
clinical histories (i.e., the timing and order of treatments and comorbidities). That is, a Markov
model captures the population-level transition rates among progression stages, but explains away
individual-level variations in progression trajectories through the randomness of the transition prob-
ability P (Zm |Zm−1, tm − tm−1). This can render Markov models highly misleading since clinical
actions are taken on an individual basis.
Interpreting the attentive state dynamics Now we use an illustrative example to show how
a clinician can interpret the attentive state dynamics for individual patients, and highlight the
information that is missed by Markovian dynamics but can be captured via attentive dynamics.
In Figure 7, we display exemplary progression tra-
jectories for 2 chronic kidney disease (CKD) pa-
tients through the unrolled graphical model of the
DBN in (2). With a slight abuse of graphical model
notation, we let the thickness of the arrows connect-
ing states be proportional to the attention weights
generated for predicting the state transition in the
third hospital visit. Patients A and B have identical
trajectories at the first 2 visits (both are diagnosed
with hypertension and are in the same progression
stages), with one exception being that Patient A is
administered a medication for hypertension (ACE
inhibitors) in the first visit. Patient B transits from
stage 2 to stage 3 CKD because of hypertensive re-
nal complications, whereas patient A stays in stage
2 thanks to the medication. The attentive model can
capture the difference between the 2 trajectories by
paying attention to the first visit for Patient A (when
the medication was prescribed), and little attention
to the same visit for Patient B.
1 2 2 
1 2 3 
Time 
Patient A 
Patient B 
 
Hypertension 
 
ACE inhibitors 
 
Hypertension 
 
States 
Observations 
Figure 7: Depiction for the attentive state dynamics.
By visually inspecting the attention weights assigned to past states of each individual patient,
clinicians can interpret the decreased risk for Patient A (compared to Patient B) to be a result of the
clinical events that Patient A encountered in the first visit (i.e., administration of ACE inhibitors). On
the contrary, a memoryless Markov model would not be able to distinguish the different trajectories
that Patients A and B exhibit as both patients are in Stage 2 CKD during the second visit.
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